Eritrea vs Guyana: Tuberculosis patients living with HIV receiving antiretroviral therapy
Eritrea
41 patients
in 2021
Guyana
53 patients
in 2021
Eritrea rank
90th
Guyana rank
87th
Tuberculosis patients living with HIV receiving antiretroviral therapy over time
- Eritrea
- Guyana
How they compare
Guyana currently reports 53 patients against 41 patients in Eritrea, a difference of 12 patients.
That makes Guyana's figure about 1.3 times Eritrea's.
The two have swapped places 6 times across 10 shared years of data; in 2012 it was Guyana ahead.
Eritrea ranks 90th and Guyana ranks 87th of 183 countries.
Across the 2 decades both report, Eritrea averaged higher in 1 and Guyana in 1.
Head to head by decade
| Decade | Eritrea | Guyana | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 75.25 patients | 102.88 patients | 27.62 patients | Guyana |
| 2020s | 49 patients | 43.5 patients | 5.5 patients | Eritrea |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher tuberculosis patients living with hiv receiving antiretroviral therapy, Eritrea or Guyana?
- Guyana, at 53 patients against 41 patients in Eritrea as of 2021.
- What is the difference in tuberculosis patients living with hiv receiving antiretroviral therapy between Eritrea and Guyana?
- 12 patients, with Guyana ahead.
- How many years of comparable data are there for Eritrea and Guyana?
- 10 years are reported by both, from 2012 to 2021.
- How do Eritrea and Guyana rank globally for tuberculosis patients living with hiv receiving antiretroviral therapy?
- Eritrea ranks 90th and Guyana ranks 87th of 183 countries.
- Where does this data come from?
- Joint United Nations Programme on HIV/AIDS (2026); Population based on various sources (2024) – with minor processing by Our World in Data, published as Tuberculosis patients living with HIV receiving antiretroviral therapy. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Number of tuberculosis patients who are living with HIV and receiving antiretroviral therapy.